Európska únia - nórčina - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride hydrate - multiple myeloma; lymphoma, follicular; myelodysplastic syndromes - immunsuppressive - multiple myelomalenalidomide krka d. as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) er indisert for behandling av voksne pasienter med tidligere ubehandlet myelomatose som ikke er kvalifisert for transplantasjon. lenalidomide krka d. in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka d. as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. follicular lymphomalenalidomide krka d. in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Nórsko - nórčina - Statens legemiddelverk

sandoz - københavn - lenalidomid - kapsel, hard - 10 mg

Nórsko - nórčina - Statens legemiddelverk

sandoz - københavn - lenalidomid - kapsel, hard - 2.5 mg

Nórsko - nórčina - Statens legemiddelverk

sandoz - københavn - lenalidomid - kapsel, hard - 5 mg

Nórsko - nórčina - Statens legemiddelverk

sandoz - københavn - lenalidomid - kapsel, hard - 7.5 mg

Nórsko - nórčina - Statens legemiddelverk

sandoz - københavn - lenalidomid - kapsel, hard - 15 mg

Nórsko - nórčina - Statens legemiddelverk

sandoz - københavn - lenalidomid - kapsel, hard - 20 mg

Nórsko - nórčina - Statens legemiddelverk

sandoz - københavn - lenalidomid - kapsel, hard - 25 mg

Európska únia - nórčina - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - antineoplastiske midler - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

Nórsko - nórčina - Statens legemiddelverk

zentiva k.s. - lenalidomid - kapsel, hard - 20 mg